Enrollment status comes from the registry; check the original record for current details.
- Registry ID
- NCT07112872
- Phase
- Phase 2
- Recruitment
- Enrolling participants
- Sponsor
- Hoffmann-La Roche
- Design
- Randomized
- Comparator
- Part A, Arm 1: Placebo; Part A, Arm 2: Semaglutide 14 mg; Part A, Arm 3: Tifeglipron Dosing Regimen 1; Part A, Arm 4: Tifeglipron Dosing Regimen 2; Part A, Arm 5: Tifeglipron Dosing Regimen 3; Part A, Arm 6: Tifeglipron Dosing Regimen 4; Part A, Arm 7: Tifeglipron Dosing Regimen 5; Part A, Arm 8: Tifeglipron Dosing Regimen 6; Part A, Arm 9: Tifeglipron Dosing Regimen 7; Part B, Arm 1: Placebo; Part B, Arm 2: Tifeglipron Dosing Regimen A; Part B, Arm 3: Tifeglipron Dosing Regimen B
- Planned enrollment
- 330
- Endpoint
- Tifeglipron vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30
Study ages: 18 Years and older. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Hungary, Poland, Spain, United States.
Sites marked recruiting: United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: Feb 5, 2028 (estimated). This is not a results-release date.
No results-posting date in this record.